搜尋結果
2024年4月9日 · The immunogenicity of aIIV3 was compared with a nonadjuvanted split virion trivalent influenza vaccine (Begrivac; Novartis Vaccines, Basel, Switzerland) and a subunit IIV3 (Agrippal) in 119 older adults aged 61–91 years during the 2003–2004 season.
2024年3月27日 · The tetravalent vaccines contain both seasonal influenza A subtypes, A (H3N2) and A (H1N1)pdm09, and both influenza B lineages, B/Victoria and B/Yamagata. It needs to be noted however that as of January 2024, influenza B/Yamagata viruses have not been circulating since March 2020. Trivalent vaccines contain one of the two B lineage virus ...
6 天前 · Influenza vaccine. Influenza vaccines, colloquially known as flu shots, are vaccines that protect against infection by influenza viruses. [12] [13] New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. [12] While their effectiveness varies from year to year, most provide modest to high protection ...
2024年3月21日 · This study assesses safety, tolerability and immunogenicity of NBP607QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease. Full description Subjects are randomly assigned in a 1:1 ratio to NBP607QIV versus Agrippal S1.
2024年4月1日 · Influenza virus vaccine Agrippal S1 (Seqirus): 一种免疫刺激剂药物，由Novartis Vaccines & Diagnostics, Inc. (诺瓦提斯疫苗和诊断公司)公司最早进行研发，作用机制: 免疫刺激剂。
2024年4月1日 · 只需点击几下即可了解关键药物信息。. IC 31 seasonal influenza vaccine (CSL/Valneva): 一种TLR9激动剂、免疫刺激剂药物，由Novartis AG (诺华有限公司)公司最早进行研发，目前全球最高研发状态为无进展，作用机制: TLR9激动剂 (Toll样受体9激动剂),免疫刺激剂，治疗领域: 感染 ...
2024年4月1日 · A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, when Administered to Non-Elderly Adult and Elderly Subjects - ND
